Question · asked by 1 review

NORADRENERGIC DRUGS vs placebo: Secondary outcome: acceptability of treatment

Population
patients with antipsychotic‐induced tardive dyskinesia
Intervention
NORADRENERGIC DRUGS
Comparison
placebo
Outcome
Secondary outcome: acceptability of treatment

It is very uncertain whether NORADRENERGIC DRUGS changes acceptability of treatment: Leaving the study early compared with PLACEBO (very low certainty).

What each review found

Include earlier review versions
FindingEffectStudiesGRADE certainty
NORADRENERGIC DRUGS vs PLACEBO
Acceptability of treatment: Leaving the study early · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether NORADRENERGIC DRUGS changes acceptability of treatment: Leaving the study early compared with PLACEBO (very low certainty).
Non‐antipsychotic catecholaminergic drugs for antipsychotic‐induced tardive dyskinesia (2018) · Cochrane Headline outcomes only
RR 5.28 [0.27, 102.58]1 study · 35 participantsVery low

Findings are shown side by side, never pooled across reviews.

The reviews

ReviewSearched up toIncluded studiesAMSTAR 2
Non‐antipsychotic catecholaminergic drugs for antipsychotic‐induced tardive dyskinesia
2018 · Cochrane Headline outcomes only
Not reportedNot extractedNot assessed

The same intervention and outcome, asked in another population or against another comparator.

How reviews are matched to this question

Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.